The Chinese Version of UHDRS in Huntington’s Disease: Reliability and Validity Assessment
Journal of Huntington's Disease · 16.12.2022 · 11 (4) · 407-413
DOI: 10.3233/jhd-220542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Huntington's Disease, erschienen am 16.12.2022. Verfasst von Xiao-Yan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Department of Medical Genetics in Second Affiliated Hospital and Key Laboratory of Medical Neurobiology of Zhejiang Provi…. Hauptthemen laut MEDLINE: Huntington Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
The Unified Huntington’s Disease Rating Scale (UHDRS) is a universal scale assessing disease severity of Huntington’s disease (HD). However, the English version cannot be widely used in China, and the reliability and validity of the Chinese UHDRS have not yet been confirmed.
Objective
To test the reliability and validity of Chinse UHDRS in patients with HD.
Methods
Between August 2013 and August 2021, 159 HD patients, 40 premanifest HD, and 64 healthy controls were consecutively recruited from two medical centers in China and assessed by Chinese UHDRS. Internal consistency and interrater reliability of the scale were examined. Intercorrelation was performed to analyze the convergent and divergent validity of the scale. A receiver operating characteristic analysis was conducted to explore the optimal cutoff point of each cognitive test.
Results
High internal consistency was found in Chinese UHDRS, and its Cronbach’s alpha values of the motor, cognitive, behavioral and functional subscales were 0.954, 0.826, 0.804, and 0.954, respectively. The interrater reliability of the total motor score was 0.960. The convergent and divergent validity revealed that motor, cognitive and functional subscales strongly related to each other except for Problem Behavior Assessment. Furthermore, we not only provided the normal level of each cognitive test in controls, but also gave the optimal cutoff points of cognitive tests between controls and HD patients.
Conclusion
We demonstrate for the first time that the translated version of UHDRS is reliable for assessing HD patients in China. This can promote the universal use of UHDRS in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology and Department of Medical Genetics in Second Affiliated Hospital and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
- Swiss Huntington's Disease Centre, Siloah, Gümligen and, Department of Neurology, University of Bern, Bern, Switzerland.
- NHC and CAMS Key Laboratory of Medical Neurobiology, MOE Frontier Science Center for Brain Research and Brain-Machine Integration, School of Brain Science and Brain Medicine, Zhejiang University, Hangzhou, China.
- CAS Center for Excellence in Brain Scienceand Intelligence Technology, Shanghai, China.
Zitieren
APA
Li, X. Y., Bao, Y. F., Xie, J. J., Qian, S. X., Gao, B., Xu, M., Dong, Y., Burgunder, J. M., & Wu, Z. Y. (2022). The Chinese Version of UHDRS in Huntington’s Disease: Reliability and Validity Assessment. Journal of Huntington's Disease, 11(4), 407-413. https://doi.org/10.3233/jhd-220542
Vancouver
Li XY, Bao YF, Xie JJ, Qian SX, Gao B, Xu M, et al. The Chinese Version of UHDRS in Huntington’s Disease: Reliability and Validity Assessment. Journal of Huntington's Disease. 2022;11(4):407-413. doi:10.3233/jhd-220542
BibTeX
@article{Li2022,
author = {Li, Xiao-Yan and Bao, Yu-Feng and Xie, Juan-Juan and Qian, Shu-Xia and Gao, Bin and Xu, Miao and Dong, Yi and Burgunder, Jean-Marc and Wu, Zhi-Ying},
title = {The Chinese Version of UHDRS in Huntington’s Disease: Reliability and Validity Assessment},
journal = {Journal of Huntington's Disease},
year = {2022},
volume = {11},
number = {4},
pages = {407--413},
doi = {10.3233/jhd-220542}
}
EUVIMED